Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide trial in children aged 6 to 11

A Phase 3 trial reported BMI changes with semaglutide in children aged 6 to under 12, alongside lifestyle counselling and safety data.

Why we wrote this. The trial is important, but its result is not a substitute for paediatric assessment, local authorisation or family-centred care.

In this article (5 sections)
  1. Who took part and what was compared
  2. The result at 68 and 104 weeks
  3. Safety findings need equal attention
  4. What the publication does not establish
  5. A careful way to discuss the study

A Phase 3 study in the New England Journal of Medicine examined once-weekly subcutaneous semaglutide in children aged 6 to under 12 with obesity. It compared semaglutide plus lifestyle-modification counselling with placebo plus the same counselling. The publication supplies a useful result for a younger age group, while leaving questions about approvals, long-term use and individual care outside the scope of one trial.[1]

Semaglutide is a GLP-1 receptor agonist, a medicine that acts on a hormone-signalling pathway involved in appetite, digestion and glucose control. In the study, it was administered by weekly subcutaneous injection. That trial description is not dosing guidance. Paediatric prescribing depends on the authorised product label, local rules and assessment by clinicians experienced in the child's care.

Who took part and what was compared

The investigators randomly assigned 167 children with obesity in a 2:1 ratio: 112 received semaglutide and 55 placebo. Both groups received counselling for lifestyle modification. The trial ran treatment for 104 weeks, with a seven-week washout after treatment, and its primary endpoint was percentage change in body-mass index, or BMI, from baseline to week 68.[1]

BMI is a screening measure calculated from weight and height. In children, its interpretation is age- and sex-specific rather than a direct copy of adult thresholds. The article therefore reports BMI changes and BMI-category outcomes; it should not be read as a target for a particular child. The registered study record identifies the trial as STEP Young, NCT05726227.[2]

The result at 68 and 104 weeks

At week 68, mean percentage change in BMI was minus 13.5% with semaglutide and plus 2.7% with placebo. The estimated between-group difference was minus 16.2 percentage points, with a 95% confidence interval from minus 19.4 to minus 12.9. The paper also reported BMI-category reduction in 79% of the semaglutide group and 23% of the placebo group at week 68.[1]

At week 104, mean BMI change was minus 9.4% with semaglutide and plus 8.4% with placebo, for a reported between-group difference of minus 17.8 percentage points. These are group averages from a controlled study. They do not predict an individual child's result, and the study's counselling component means the result does not isolate medicine from the care programme around it.[1]

Safety findings need equal attention

Adverse events occurred in 96% of participants assigned semaglutide and 93% assigned placebo. Gastrointestinal events were the most common, occurred more often with semaglutide and led to discontinuation in one participant in the semaglutide group. The abstract does not turn those figures into a universal risk estimate, so they need to remain tied to this 167-child trial and its follow-up period.[1]

Any possible adverse effect in a child deserves timely discussion with the treating team. New or worsening symptoms, missed doses, treatment access or questions about another medicine are not matters for online self-management. A family's clinician can consider medical history, growth, mental wellbeing, other medicines and the product information that applies where they live.

What the publication does not establish

The paper says that data for semaglutide in younger children had been lacking and reports a controlled result over the study period. It does not itself establish an approval for children aged 6 to under 12 in every country, nor does it resolve very long-term outcomes beyond the trial. Regulatory status must be checked separately, including on the site's semaglutide regulation page.[1]

It also does not compare semaglutide with every other obesity intervention or establish that one study result should change care without professional assessment. The trial enrolled children with obesity under defined eligibility criteria. Readers can use our semaglutide page and GLP-1 coverage to place the study among related evidence, but those pages are not a replacement for clinical advice.

The study record and journal report answer different parts of the same question. The paper reports the measured outcomes; the registry records the trial identity and design. Neither gives a family a universal treatment plan. For related background, the site separates semaglutide mechanism, semaglutide safety, semaglutide evidence and regulation so readers can distinguish evidence from a product decision.

The authors also describe uncertainty as a reason for caution. Results from a registered protocol, a peer-reviewed report and a product label each answer different questions about a medicine.

A careful way to discuss the study

For families, useful questions are factual rather than self-prescriptive: What exactly was studied? Which outcomes were measured? What adverse events were reported? Does the relevant authority permit this product for this age and indication? And how would a clinician weigh the child's wider health and support needs? The study contributes evidence to those discussions. It does not create a general instruction to seek, use or avoid a medicine.

PeptideMethods' regulation hub explains why a journal publication and a marketing authorisation answer different questions. The distinction is particularly important in paediatrics, where trial evidence, product labelling and local service arrangements may move on different timelines.

Frequently asked

What age group did the study include?

The trial enrolled children aged 6 to under 12 with obesity. Its findings should not be assumed to apply to adolescents, adults or children outside the study criteria.

What did the trial measure?

The primary outcome was percentage change in BMI from baseline to week 68. The investigators also reported BMI-category change and safety findings.

Was semaglutide used alone?

No. Both trial groups received lifestyle-modification counselling, so the study compared semaglutide plus counselling with placebo plus counselling.

Does this paper mean semaglutide is approved for all children?

No. A trial publication is not an authorisation. Product approval and eligibility vary by jurisdiction and require checking against the current official label and local clinical advice.

Sources

  1. [1]Jastreboff et al. Semaglutide for the Treatment of Obesity in Children 6 to Under 12 Years of Age (NEJM, 2026; PMID 43037562)Tier 1 · primary↩
  2. [2]STEP Young study record, NCT05726227 (ClinicalTrials.gov)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars